Published in Vaccine Weekly, January 1st, 2003
Filiberto Belli and colleagues working in Italy and the U.S. vaccinated 42 patients who had stage IV malignant melanoma with at least one cycle (four weekly injections) of a vaccine containing autologous, tumor-derived heat shock protein gp96-peptide complexes (HSPPC-96). Twenty-one of the patients in whom no progression occurred received a second cycle consisting of four biweekly...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly